Roche at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Roche brings 2 presentations to ASH 2026 in New Orleans. Its program centres on lymphoma, with research on gene therapy for hemophilia A as well. It supports a symposium on sequencing bispecifics in DLBCL and presents work on standardizing response criteria from PET and CT scans.
| Organization | ASH 2026 Attendance |
|---|---|
Roche Basel, Switzerland | |
Swiss pharmaceutical and diagnostics company; its hematology medicines include bispecific antibodies for lymphoma. | Symposium Fri Dec 11 7:00pm–10:00pm Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care Where bispecific antibodies fit in diffuse large B-cell lymphoma, weighed against CAR-T by patient fitness, access, and T-cell health. Oral Sun Dec 13 9:30am–11:00am |
Find decision makers at Roche
Tell us what you sell and we’ll find the people at Roche most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction